Journal of Autism and Developmental Disorders

, Volume 25, Issue 5, pp 481–493

Efficacy of vitamin B6 and magnesium in the treatment of autism: A methodology review and summary of outcomes

  • Steven I. Pfeiffer
  • Jennifer Norton
  • Laura Nelson
  • Susan Shott
Article

Abstract

Pauling's orthomolecular hypothesis appeared in 1968, stating that some forms of mental illness and disease are related to biochemical errors in the body. Vitamin therapy is believed to be a means of compensating for such errors. There have been few empirical studies on vitamin therapy in individuals with autism. This article presents a critical analysis of the 12 published studies located through an extensive computerized search. Studies were systematically evaluated to provide an objective assessment of empirical evidence supporting the efficacy of vitamin treatment. The majority of studies report a favorable response to vitamin treatment. However, interpretation of these positive findings needs to be tempered because of methodological shortcomings inherent in many of the studies. For example, a number of studies employed imprecise outcome measures, were based on small samples and possible repeat use of the same subjects in more than one study, did not adjust for regression effects in measuring improvement, and omitted collecting long-term follow-up data. Recommendations are offered to assist researchers in designing future investigations.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barthelemy, C., Garreau, B., Leddet, I., Ernouf, D., Muh, J. P., & Lelord, G. (1981). Behavioral and biological effects of oral magnesium, vitamin B6 administration in autistic children.Magnesium-Bulletin, 2, 150–153.Google Scholar
  2. Barthelemy, C., Garreau, B., Leddet, I., Sauvage, D., Domenech, J., Muh, J. P., & Lelord, G. (1980). Biological and clinical effects of oral magnesium and associated magnesium-vitamin B6 administration of certain disorders observed in infantile autism.Therapie, 35, 627–632.Google Scholar
  3. Barthelemy, C., Garreau, B., Leddet, I., Sauvage, D., Muh, J. P., Lelord, G., & Callaway, E. (1983). Interest of behavioral scales and determination levels of urinary homovanillic acid for the control of the effects of a treatment associating vitamin B6 and magnesium in children presenting an autistic behavior.Neuropsychiatirie de l'Enfance, 31, 289–301.Google Scholar
  4. Barthelemy, C., Martineau, J., Bruneau, N., Muh, J. P., Lelord, G., & Callaway, E. (1988). Clinical and biological effects of pyridoxine plus magnesium in autistic subjects. In J. E. Leklem & R. D. Reynolds (Eds.),Clinical and physiological applications of vitamin B-6 (pp. 329–356). New York: Alan R. Liss.Google Scholar
  5. Bonisch, V. (1968). Experience with pyrithioxin in brain damaged children with autistic syndrome.Praxis der Kinderpsychologie, 8, 308–310.Google Scholar
  6. Damasio, A., & Maurer, R. (1978). A neurological model for childhood autism.Archives of Neurology, 35, 778–796.Google Scholar
  7. Garreau, B., Barthelemy, C., Domenech, J., Sauvage, D., Muh, J. P., Callaway, E., & Lelord, G. (1980). Troubles du metabolisme de la dopamine chez des enfants ayant un comportement autistique: Resultats des examens cliniques et des dosages urinaires de l'acide homovanilique (AHV).Acta Psychiatrica Belgium, 80, 240–265.Google Scholar
  8. Gualtieri, C., Golden, R., & Fahs, J. (1983). New developments in pediatric psychopharmacology.Developmental and Behavioral Pediatrics, 3, 202–209.Google Scholar
  9. Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful change in psychotherapy research.Journal of Consulting and Clinical Psychology, 59, 12–19.Google Scholar
  10. Jonas, C., Etienne, T., Barthelemy, C., Jouve, J., & Mariotte, N. (1984). Clinical and biochemical advantage of associated vitamin B6 and magnesium in the treatment of infantile autism residual state, in adulthood.Therapie, 39, 37–52.Google Scholar
  11. Kazdin, A. E. (1988).Child psychotherapy and behavior change (3rd ed., pp. 23–68). New York: Wiley.Google Scholar
  12. Kazdin, A. E. (1993). Treatment of conduct disorder: Progress and directions in psychotherapy research.Development and Psychopathology, 5, 277–310.Google Scholar
  13. Lelord, G., Callaway, E., Muh, J. P., Arlot, J. C., Sauvage, D., Garreau, B., & Domenech, J. (1978). Modifications in urinary homovanillic acid after ingestion of vitamin B6: Functional study in autistic children.Revue Neurologigue, 134, 797–801.Google Scholar
  14. Lelord, G., Muh, J. P., Barthelemy, C., Martineau, J., & Garreau, B. (1981). Effects of pyridoxine and magnesium on autistic symptoms—initial observations.Journal of Autism and Developmental Disorders, 11, 219–230.Google Scholar
  15. Lipsey, M. W. (1990).Design sensitivity: Statistical power for experimental research. Newbury Park, CA: Sage.Google Scholar
  16. Martineau, J., Barthelemy, C., Cheliakine, C., & Lelord, G. (1988). Brief report: An open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to treatment.Journal of Autism and Developmental Disorders, 18, 435–447.Google Scholar
  17. Martineau, J., Barthelemy, C., Garreau, B., & Lelord, G. (1985). Vitamin B6, magnesium, and combined B6-magnesium: Therapeutic effects in childhood autism.Biological Psychiatry, 20, 467–478.Google Scholar
  18. Martineau, J., Barthelemy, C., & Lelord, G. (1986). Long-term effects of combined vitamin B6-magnesium administration in an autistic child.Biological Psychiatry, 21, 511–518.Google Scholar
  19. Martineau, J., Barthelemy, C., Roux, S., Garreau, B., & Lelord, G. (1989). Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behavior.Developmental Medicine and Child Neurology, 31, 721–727.Google Scholar
  20. Martineau, J., Garreau, B., Barthelemy, C., Callaway, E., & Lelord, G. (1981). Effects of vitamin B6 on averaged evoked potentials in infantile autism.Biological Psychiatry, 16, 627–640.Google Scholar
  21. Martineau, J., Garreau, B., Barthelemy, C., & Lelord, G. (1982). Comparative effects of oral B6Mg and Mg administration on evoked potentials conditioning in autistic children. In A. Rothenberger (Ed.),Event-related potentials in children (pp. 411–416). New York: Elsevier.Google Scholar
  22. Morgan, S. (1986). Early childhood autism: Changing perspectives.Journal of Child and Adolescent Psychiatry, 3, 3–9.Google Scholar
  23. Moore, R., & Bloom, F. (1978). Central catecholamine neuron systems: Anatomy and physiology of the norepinephrine and epinephrine systems.Annual Review of Neuroscience, 2, 129–169.Google Scholar
  24. Muscettola, G., Wehr, T. A., & Goodwin, F. K. (1977). Effect of diet on urinary MHPG excretion in depressed patients and normal control subjects.American Journal of Psychiatry, 134, 914–916.Google Scholar
  25. Naglieri, J. A., LeBuffe, P. A., & Pfeiffer, S. I. (1994).Devereux scales of mental disorders manual San Antonio, TX: Psychological Corp.Google Scholar
  26. Pauling, L. (1968). Orthomolecular psychiatry.Science, 160, 265–271.Google Scholar
  27. Pfeiffer, S. I. (1989). Follow-up of children and adolescents treated in psychiatric facilities: A methodology review.Psychiatric Hospital, 20(1), 15–20.Google Scholar
  28. Pfeiffer, S. I. (1990). An analysis of methodology in follow-up studies of adult inpatient psychiatric treatment.Hospital and Community Psychiatry, 41, 1315–1321.Google Scholar
  29. Pfeiffer, S. I., Soldivera, S., & Norton, J. (1992).A consumer's guide to mental health treatment outcome measures. Devon, PA: The Devereux Foundation.Google Scholar
  30. Potter, W. Z., Hsiao, J. K., & Goldman, S. M. (1989). Effects of renal clearance on plasma concentrations of homovanillic acid.Archives of General Psychiatry, 46, 558–562.Google Scholar
  31. Rimland, B., Callaway, E., & Dreyfus, P. (1978). The effects of high doses of vitamin B6 on autistic children.American Journal of Psychiatry, 135, 472–475.Google Scholar
  32. Rosenthal, R. (1990). How are we doing in soft psychology?American Psychologist, 45, 775–777.Google Scholar
  33. Rutter, M. (1991). Autism: Pathways from syndrome definition to pathogenesis.Comprehensive Mental Health Care, 1, 5–26.Google Scholar
  34. Schafer, E., & MacKean, C. (1975). Evidence that monoamines influence human evoked potentials.Brain Research, 99, 49–58.Google Scholar
  35. Small, J., Demyer, M., & Kendall, J. (1969). Experience with response averaging in autistic children.Electroencephalography and Clinical Neurophysiology, 26, 112–113.Google Scholar
  36. Speer, D. C. (1992). Clinically significant change: Jacobson and Truax (1991) revisited.Journal of Consulting and Clinical Psychology, 60, 402–408.Google Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • Steven I. Pfeiffer
    • 1
  • Jennifer Norton
    • 2
  • Laura Nelson
    • 1
  • Susan Shott
    • 1
  1. 1.Devereux Institute of Clinical Training & Research and University of Pennsylvania School of MedicineUSA
  2. 2.New York UniversityUSA
  3. 3.Department of PsychologyDrexel UniversityPhiladelphia

Personalised recommendations